Results 1 to 10 of about 470,595 (308)

ESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice [PDF]

Brain and Behavior
Background Anti‐CGRP antibodies are effective and safe in real‐world migraine management, but guidelines recommend discontinuation after 12–18 months due to limited long‐term data and remaining uncertainties regarding optimal treatment duration and ...
Alba Somovilla, Iris Fernández‐Lázaro, Josué Pagán, Daniel Saiz, Javier Díaz‐De‐Terán, Leonardo Portocarrero Sánchez, Germán Latorre, Carlos Calle De Miguel, Nuria González‐García, María‐Luz Cuadrado, Jesús Porta‐Etessam, Javier Casas‐Limón, David Garcia‐Azorin, Ángel Guerrero‐Peral, Yésica González‐Osorio, Alicia Gonzalez‐Martinez, Guillermo Martín Ávila, Rodrigo Terrero Carpio, Jaime Rodríguez‐Vico, Alex Jaimes, Andrea Gómez García, Cristina Trevino‐Peinado, Margarita Sanchez‐Del‐Rio, Alberto Lozano Ros, Antonio Sánchez‐Soblechero, Sarai Urtiaga Valle, Marta González‐Salaices, Elena Riva, Ana Gago‐Veiga   +28 more
doaj   +2 more sources

Headache [PDF]

Current Opinion in Neurology, 2005
Headache can be divided into primary headache and secondary headache. In primary headache the headache syndrome, i.e. the head pain and any associated features, are the disease process. In secondary headache the headache syndrome is a symptom of an underlying disorder.
Sharon K, Bal, Gary R, Hollingworth
  +9 more sources

Headaches [PDF]

BMJ, 2007
Headaches and migraine occur frequently in children and adolescents and may have a significant impact on the child's and parents' lives. Recent advances in diagnosis, epidemiology, and treatment have improved the outcomes of children with headaches. This review summarizes some of these findings.Recent studies have revealed the increasing incidence of ...
Geraint, Fuller, Claire, Kaye
openaire   +4 more sources

Early and Delayed Rebound Intracranial Hypertension following Epidural Blood Patch in a Case of Spontaneous Intracranial Hypotension

Case Reports in Neurological Medicine, 2022
Background. Spontaneous intracranial hypotension (SIH) is a secondary headache that has been attributed to a cerebrospinal fluid (CSF) leak. It may resolve spontaneously or require conservative treatment.
Elham Jafari, Maryam Karaminia, Mansoureh Togha   +2 more
doaj   +1 more source

Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study

The Journal of Headache and Pain, 2021
Background Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent the first disease-specific preventive migraine therapy.
Bottiroli Sara, Roberto De Icco, Gloria Vaghi, Stefania Pazzi, Elena Guaschino, Marta Allena, Natascia Ghiotto, Daniele Martinelli, Cristina Tassorelli, Grazia Sances   +9 more
doaj   +1 more source

Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?

The Journal of Headache and Pain, 2020
Background Migraine can manifest with an episodic or a chronic pattern in a continuum of disease severity. Multiple factors are associated with the progression of the pattern from episodic to chronic.
Rosaria Greco, Roberto De Icco, Chiara Demartini, Anna Maria Zanaboni, Elena Tumelero, Grazia Sances, Marta Allena, Cristina Tassorelli   +7 more
doaj   +1 more source

Trajectory of blood pressure after initiating anti-calcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration

The Journal of Headache and Pain, 2023
Background Calcitonin gene-related peptide (CGRP) is involved in migraine pathophysiology and blood pressure regulation. Although clinical trials have established the cardio-cerebrovascular safety profile of anti-CGRP treatment, limited high-quality real-
Kaicheng Wang, Brenda T. Fenton, Vinh X. Dao, Alexander B. Guirguis, Sarah E. Anthony, Melissa Skanderson, Jason J. Sico   +6 more
doaj   +1 more source

Six-month therapy of CGRP monoclonal antibodies in real-world clinical practice: an interim analysis of efficacy and safety data

Медицинский совет, 2022
Introduction. Migraine is one of the most common disabling neurological disorders. Recently developed monoclonal antibodies to calcitonin gene-related peptide (CGRP) or its receptor are the first targeted medication for preventive therapy of both ...
N. V. Vashchenko, A. M. Uzhakhov, M. V. Bogorodskaya, D. Z. Korobkova, Ju. E. Azimova, K. V. Skorobogatykh   +5 more
doaj   +1 more source

Results of a Web-based survey of 2105 Greek migraine patients in 2020: demographics, clinical characteristics, burden and the effects of the COVID-19 pandemic on the course of migraine

BMC Neurology, 2022
The Greek Society of Migraine and Headache Patients (GSMHP), maintaining a strong commitment to research and information, conducted its second web-based online survey named "Migraine in Greece—2020", following its first one conducted in 2018.
Emmanouil V. Dermitzakis, Aikaterini Kouroudi, Andreas A. Argyriou, Konstantinos C. Spingos, Konstantinos Bilias, Michail Vikelis   +5 more
doaj   +1 more source

Calcitonin gene-related peptide causes migraine aura

The Journal of Headache and Pain, 2023
Background Although the involvement of calcitonin gene-related peptide (CGRP) in migraines is well-established, its specific role in investigating the aura phase, which often precedes the headache, remains largely unexplored. This study aims to instigate
Haidar M. Al-Khazali, Håkan Ashina, Astrid Wiggers, Kathrine Rose, Afrim Iljazi, Rune Häckert Christensen, Henrik Winther Schytz, Faisal Mohammad Amin, Messoud Ashina   +8 more
doaj   +1 more source